• Cynthia Farquhar, Paul M Brown, and Sue Furness.
• Cochrane Menstrual Disorders and Subfertility Group, Department of Obstetrics and Gynaecology, National Women's Hospital, University of Auckland, New Zealand.
• BJOG. 2002 Nov 1;109(11):1273-80.

ObjectiveTo conduct a cost effectiveness analysis of pre-operative gonadotrophin releasing hormone agonists (GnRHa) in women with uterine fibroids undergoing hysterectomy or myomectomy.DesignA cost effectiveness analysis using the effectiveness data from a systematic review of GnRHa.SettingSecondary care.SampleWomen with uterine fibroids undergoing hysterectomy or myomectomy and women volunteers.MethodsEffectiveness data were used from a systematic review to construct a model and to calculate the cost per surgical outcome avoided. In order to evaluate the value women place on the outcome, a willingness to pay analysis of women volunteers was undertaken.Main Outcome Measures(a) The cost of avoiding abdominal hysterectomy and the cost of avoiding a vertical incision at either hysterectomy or myomectomy; (b) The value that women place on avoiding abdominal hysterectomy and on avoiding a vertical incision at either hysterectomy or myomectomy. All costs are in NZ dollars.ResultsFor hysterectomy, the additional cost of treatment with GnRHa was NZ$1190 per case. The cost of avoiding one abdominal procedure was NZ$4577 per case and the cost of avoiding one vertical incision was NZ$6263. For a myomectomy, the additional cost of treatment with GnRHa was NZ$1535 per case. The cost of avoiding one vertical incision was NZ$4651 per case. These costs exceeded the benefit women placed on the outcomes.ConclusionAlthough the pre-operative use of GnRHa results in benefits which include less frequent abdominal incisions in the case of hysterectomy and less frequent vertical incisions in the case of myomectomy, the benefits do not justify the costs. This study highlights the importance of considering both the benefits and costs in health care decisions.

27 keywords...

hide…